2011 Late-Breaking Science Program Schedule

Following is the schedule of Late-Breaking Science abstracts to be presented at the 2011 AAN Annual Meeting. Abstracts qualify for Late-Breaking Science presentations by having key aspects of research conducted after the October 25th abstract submission deadline and must be new and of sufficient scientific importance to warrant expedited presentation and publication.

Poster Session II: Late-Breaking Science – Tuesday, April 12, 2011

HCC Kamehameha II, Poster Session II, 7:30 a.m. – 12:00 p.m. (Senior Authors stand-by time 7:30 a.m. – 9:00 a.m.)

P02.287 — "Serum Measurement of Hypoxia-Induced Amyloid Beta 1-42 Following Resuscitation from Cardiac Arrest" — David Wilson, Cambridge, MA

P02.288 — "Aberrant Cross Regulation of a Network of RNA-binding Proteins in Amyotrophic Lateral Sclerosis" — Liang Lu, Birmingham, AL

P02.289 — "Improvements in Muscle Function and Accidental Falling in Ataluren-Treated Patients with Nonsense Mutation Dystrophinopathy (Duchenne/Becker Muscular Dystrophy — nmDBMD)" — Craig McDonald, Sacramento, CA

P02.290 — "Neurological Disorders in Iraqi Refugees: Data from the United Nations Refugee Assistance Information System (RAIS)" — Farrah Mateen, Baltimore, MD

P02.291 — "Human induced pluripotent stem cells as a model for Charcot-Marie-Tooth disease type 2A" — Mario Saporta, San Francisco, CA

Poster Session V: Late-Breaking Science — Wednesday, April 13, 2011

HCC Kamehameha II, Poster Session V, 2:00 p.m. – 6:30 p.m. (Senior Authors stand-by time 5:00 p.m. – 6:30 p.m.)

P05.287 — "First long-term (2-year) controlled study to evaluate treatment with safinamide as add-on to levodopa in patients with Parkinson's disease and motor fluctuations" — Ravi Anand, St. Moritz, Graubünden, Switzerland

P05.288 — "Exercise and Gait-Related Disability in Parkinson Disease" — Lisa Shulman, Baltimore, MD

P05.289 — "Gestational ultraviolet and vitamin D exposure and the risk of multiple sclerosis in the United Kingdom" —Giulio Disanto, Oxford, United Kingdom

P05.290 — "Assessing Synchronous Cortical Activity in Multiple Sclerosis with Magnetoencephalography" — Adam Carpenter, Minneapolis, MN

P05.291 —"Work intensity of neurologists vs. other specialties: Shuttering the misconceptions underlying the disparities in the reimbursement for physicians' work" — Jerzy Szaflarski, Cincinnati, OH

LBS: Late Breaking Science — Wednesday, April 13, 2011

HCC Ballroom B, 5:00 p.m. – 6:00 p.m.

LBS.001 — "Double-Blind, Placebo-Controlled Fixed-Dose Trial of IPX066, a Novel Carbidopa-Levodopa (CD-LD) Extended-Release Formulation, in Early Parkinson's Disease (APEX-PD Trial)" — Rajesh Pahwa, Kansas City, KS

LBS.002 — "Global phase III trial of perampanel, a selective, non-competitive AMPA receptor antagonist, as adjunctive therapy in patients with refractory partial-onset seizures" — Jacqueline French, New York, NY

LBS.003 — "Safety and Feasibility of Intranigral and Intraputaminal CERE-120 (AAV2-neurturin) administration in Parkinson's Disease" — Joao Siffert, San Diego, CA

LBS.004 — "Polymorphisms in the receptor tyrosine kinase MERTK gene are associated with Multiple Sclerosis susceptibility" — Trevor Kilpatrick, Carlton South, New South Wales, Australia

IN9: Opticospinal Multiple Sclerosis — Thursday, April 14, 2011

HIL Tapa II, 2:30 p.m. – 3:30 p.m.

IN9-1.016 — "Primary retinal pathology in neuromyelitis optica irrespective of optic neuritis detected by optical coherence tomography" — Nam-Hee Kim, Goyang-si, South Korea

Clinical Trials Session — Friday, April 15, 2011

HCC Ballroom AB, 12:00 p.m. – 1:30 p.m.

"Oral Laquinimod Reduced Relapse Rate and Delayed Progression of Disability in Allegro, a Placebo-Controlled Phase III Trial for Relapsing-Remitting Multiple Sclerosis" — Giancarlo Comi, Milan, Italy